Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.18 USD
Change Today +0.06 / 0.98%
Volume 677.9K
CO On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

china cord blood corp (CO) Snapshot

Open
$6.14
Previous Close
$6.12
Day High
$6.24
Day Low
$6.02
52 Week High
04/24/15 - $7.24
52 Week Low
12/15/14 - $4.10
Market Cap
451.2M
Average Volume 10 Days
185.6K
EPS TTM
$0.26
Shares Outstanding
73.0M
EX-Date
--
P/E TM
23.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA CORD BLOOD CORP (CO)

china cord blood corp (CO) Related Businessweek News

No Related Businessweek News Found

china cord blood corp (CO) Details

China Cord Blood Corporation, together with its subsidiaries, primarily provides umbilical cord blood storage and ancillary services in the People’s Republic of China. The company provides cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as offers matching services. As of March 31, 2014, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company has a strategic collaboration with Cord Blood Registry to share data on cord blood collection, processing, and storage. China Cord Blood Corporation is based in Central, Hong Kong.

944 Employees
Last Reported Date: 07/31/14

china cord blood corp (CO) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $701.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $701.0K
Chief Executive Officer of Guangdong Division...
Total Annual Compensation: $435.2K
Chief Executive Officer of Beijing Division
Total Annual Compensation: $244.3K
Chief Technology Officer
Total Annual Compensation: $177.3K
Compensation as of Fiscal Year 2014.

china cord blood corp (CO) Key Developments

China Cord Blood Corporation Announces Resignation of Julian J. Wolhardt as Board of Directors, Compensation Committee and Nominating and Corporate Governance Committee

China Cord Blood Corporation announced that Mr. Julian J. Wolhardt, one of the company's independent directors, has resigned from the board of directors effective May 13, 2015. Upon his resignation, Mr. Wolhardt will also cease to be a member of each of the company's Compensation Committee and Nominating and Corporate Governance Committee.

China Cord Blood Corporation Announces Unaudited Consolidated Financial Results for the Third Quarter and First Nine Months Ended December 31, 2014

China Cord Blood Corporation announced unaudited consolidated financial results for the third quarter and first nine months ended December 31, 2014. Revenues for the third quarter of fiscal 2015 increased by 10.7% to RMB 166.7 million ($26.9 million) from RMB 150.6 million in the prior year period. Operating income increased to RMB 67.8 million ($10.9 million) from RMB 65.7 million in the prior year period, despite higher depreciation expense as a result of the completion of the new facilities and the first time recognition of share-based compensation expense related to the restricted share units (RSUs) granted. Operating income before depreciation and amortization and share-based compensation expenses was RMB 83.2 million ($13.4 million), up 9.9% year-over-year from RMB 75.692 million a year ago. Net income attributable to the Company's shareholders was RMB 33.4 million ($5.4 million) or RMB 0.41 per basic and diluted share, compared to RMB 34.6 million or RMB 0.41 per basic and diluted share in the prior year period. Net cash provided by operating activities for the quarter was RMB 152.7 million ($24.6 million) after taking into account the interest payment made to the Company's convertible note holder, compared to RMB 168.993 million a year ago. The increases in processing revenues and recurring storage revenues were mainly driven by the solid year-over-year growth of new subscribers and the Company's enlarged total subscriber base. Due to higher interest expense, which offset the increase in operating income, income before income tax for the third quarter decreased year-over-year to RMB 47.1 million ($7.6 million) from RMB 49.2 million. Revenues for the first nine months of fiscal 2015 increased by 12.2% to RMB 472.1 million ($76.1 million) from RMB 420.9 million in the prior year period. Operating income increased by 10.5% to RMB 185.5 million ($29.9 million) from RMB 167.9 million in the prior year period. Operating income before depreciation and amortization and share-based compensation expenses was RMB 225.6 million ($36.4 million), up 15.6% year-over-year from RMB 195.170 million a year ago. Net income attributable to the Company's shareholders was RMB 90.4 million ($14.6 million) or RMB 1.13 per basic and diluted share, compared to RMB 92.4 million or RMB 1.14 per basic and diluted share in the prior year period. Net cash provided by operating activities for the first nine months of fiscal 2015 increased by 12.5% to RMB 448.4 million ($72.3 million) from RMB 398.6 million in the prior year period. The increase in revenue was largely attributable to the steady growth of new subscribers and the Company's expanded subscriber base, which reached 425,377 at the end of December 2014. Income before income tax was RMB 126.108 million against RMB 138.392 million a year ago.

China Cord Blood Corporation, Q3 2015 Earnings Call, Feb 26, 2015

China Cord Blood Corporation, Q3 2015 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CO:US $6.18 USD +0.06

CO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CO.
View Industry Companies
 

Industry Analysis

CO

Industry Average

Valuation CO Industry Range
Price/Earnings 23.9x
Price/Sales 5.0x
Price/Book 1.9x
Price/Cash Flow 21.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA CORD BLOOD CORP, please visit www.chinacordbloodcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.